{
 "id": "xpertsystems/hc-end-007-sample",
 "owner": "xpertsystems",
 "name": "hc-end-007-sample",
 "downloads": 37,
 "likes": 0,
 "last_modified": "2026-05-29T13:34:39.000Z",
 "stated_licence": "cc-by-nc-4.0",
 "stated_from": "tag",
 "licence_name": null,
 "licence_link": null,
 "file_licence": null,
 "licence_files": [],
 "sources": [],
 "gated": false,
 "tasks": [
  "tabular-classification",
  "tabular-regression",
  "survival-analysis"
 ],
 "citation": "@dataset{xpertsystems_hc_end_007_2026,\n  title        = {HC-END-007: Osteoporosis & Metabolic Bone Disease Synthetic Dataset},\n  author       = {XpertSystems.ai},\n  year         = {2026},\n  publisher    = {XpertSystems.ai Synthetic Data Factory},\n  url          = {https://xpertsystems.ai},\n  note         = {Synthetic; CC-BY-NC-4.0 (sample). Drug efficacy hard-anchored to: FIT\n                  (alendronate; Black et al. 1996); HORIZON (zoledronic acid; Black et al.\n                  2007, NEJM); FREEDOM (denosumab; Cummings et al. 2009, NEJM); FRAME and\n                  ARCH (romosozumab; Cosman 2016, Saag 2017, NEJM); MORE (raloxifene);\n                  WHI (hormone therapy). BMD reference: NHANES III (Looker et al. JBMR 1995).\n                  Fracture risk: WHO FRAX algorithm; treatment thresholds per NOF/Bone Health\n                  & Osteoporosis Foundation guidelines.}\n}",
 "signal": "restrictive",
 "reason": "The declared licence (cc-by-nc-4.0) is classified as having use restrictions.",
 "revision": "e6a82bc901325166a380c94d2e08dcc8d0b5a9c0",
 "stated_evidence": "https://huggingface.co/datasets/xpertsystems/hc-end-007-sample/blob/e6a82bc901325166a380c94d2e08dcc8d0b5a9c0/README.md",
 "file_evidence": "https://huggingface.co/datasets/xpertsystems/hc-end-007-sample/tree/e6a82bc901325166a380c94d2e08dcc8d0b5a9c0",
 "card_nc": false
}